US too withdraws hydroxychloroquine trialsJune 21, 2020
The US National Institutes of Health has halted its clinical trials on hydroxychloroquine (HCQ) for the treatment of COVID-19 patients hospitalised with severe symptoms. The NIH had initiated this trial on a large number of patients to evaluate the safety and effectiveness of this malaria drug after it was touted as a wonder drug for the treatment of coronavirus disease.
The NIH said on Saturday that its study failed to prove any positive results as the drug did not show any benefit to the patients even though it did no harm. The World Health Organisation had last week announced that it has completely halted the trials on HCQ as its clinical study under the Solidarity trial project did not show any encouraging results.
The US president Donald Trump has been quite optimistic and very vocal about the efficacy of this age-old antiviral drug for the treatment of COVID-19. Since India is one of the largest producers of this generic drug in the world currently, the US President had even threatened India of dire consequences if the latter fails to supply enough quantity of the drug to US. India too had relied on this drug for managing the disease and had put a partial ban on the export of this drug.